Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Psychiatry, Seoul National University Bundang Hospital, Seongnam, Korea.
Yonsei Med J. 2021 Jun;62(6):528-534. doi: 10.3349/ymj.2021.62.6.528.
Studies have reported mixed results on the association between benzodiazepine use and mortality. Here, we investigated whether benzodiazepine use is associated with a higher risk of 5-year all-cause mortality, and examined the association between benzodiazepine use and 5-year disease-specific mortality.
In this population-based cohort study, a nationally representative sample cohort in South Korea was examined. In 2010, benzodiazepine users were defined as individuals prescribed benzodiazepine continuously over 30 days for regular administration, and all other subjects were included in the control group. The primary endpoint was 5-year all-cause mortality, evaluated from 2011 to 2015. Propensity score (PS) matching and time-dependent Cox regression were performed for statistical analysis, which included benzodiazepine use during 2011-2015 as a time-dependent variable.
A total of 822414 adult individuals were included in the final analysis, and the all-cause 5-year mortality was recorded in 20991 individuals (2.7%). The benzodiazepine group included 30837 patients and the control group comprised 791377 patients. After PS matching, 61672 individuals (30836 in each group) were included in the final analysis. After PS matching, the 5-year all-cause mortality in the benzodiazepine group was 10.0% (3082/30836), whereas that in the control group was 9.4% (2893/30836). In time-dependent Cox regression analysis of the PS-matched cohort, the benzodiazepine group showed 1.15-fold higher 5-year all-cause mortality (hazard ratio: 1.15, 95% confidence interval: 1.09-1.22; <0.001) compared to the control group.
Benzodiazepine use was associated with increased 5-year all-cause mortality in the South Korean adult population. Further studies are needed to confirm these findings.
研究报告称，苯二氮䓬类药物的使用与死亡率之间的关联存在差异。在此，我们研究了苯二氮䓬类药物的使用是否与更高的 5 年全因死亡率风险相关，并检查了苯二氮䓬类药物的使用与 5 年疾病特异性死亡率之间的关联。
在这项基于人群的队列研究中，我们检查了韩国的一个全国代表性样本队列。2010 年，将连续 30 天以上开处苯二氮䓬类药物用于常规给药的患者定义为苯二氮䓬类药物使用者，所有其他患者被纳入对照组。主要终点为 2011 年至 2015 年的 5 年全因死亡率。进行倾向评分（PS）匹配和时间依赖性 Cox 回归分析，其中将 2011-2015 年期间的苯二氮䓬类药物使用作为时间依赖性变量。
共有 822414 名成年人纳入最终分析，20991 人（2.7%）记录了全因 5 年死亡率。苯二氮䓬类药物组包括 30837 名患者，对照组包括 791377 名患者。在进行 PS 匹配后，共有 61672 名患者（每组 30836 名）纳入最终分析。在 PS 匹配后，苯二氮䓬类药物组的 5 年全因死亡率为 10.0%（3082/30836），而对照组为 9.4%（2893/30836）。在 PS 匹配队列的时间依赖性 Cox 回归分析中，苯二氮䓬类药物组的 5 年全因死亡率比对照组高 1.15 倍（风险比：1.15，95%置信区间：1.09-1.22；<0.001）。
在韩国成年人群中，苯二氮䓬类药物的使用与 5 年全因死亡率的增加相关。需要进一步的研究来证实这些发现。
